Diversity index of mucosal resident T lymphocyte repertoire predicts clinical prognosis in gastric cancer
Abstract
© 2015 Taylor & Francis Group, LLC.A characteristic immunopathology of human cancers
is the induction of tumor antigen-specific T lymphocyte responses within solid tumor
tissues. Current strategies for immune monitoring focus on the quantification of the
density and differentiation status of tumor-infiltrating T lymphocytes; however, properties
of the TCR repertoire - including antigen specificity, clonality, as well as its prognostic
significance β remain elusive. In this study, we enrolled 28 gastric cancer patients
and collected tumor tissues, adjacent normal mucosal tissues, and peripheral blood
samples to study the landscape and compartmentalization of these patients’ TCR β repertoire
by deep sequencing analyses. Our results illustrated antigen-driven expansion within
the tumor compartment and the contracted size of shared clonotypes in mucosa and peripheral
blood. Most importantly, the diversity of mucosal T lymphocytes could independently
predict prognosis, which strongly underscores critical roles of resident mucosal T-cells
in executing post-surgery immunosurveillance against tumor relapse.
Type
Journal articlePermalink
https://hdl.handle.net/10161/11568Published Version (Please cite this version)
10.1080/2162402X.2014.1001230Publication Info
Jia, Qingzhu; Zhou, Junfeng; Chen, Gang; Shi, Yan; Yu, Haili; Guan, Peng; ... Wan,
Ying (2015). Diversity index of mucosal resident T lymphocyte repertoire predicts clinical prognosis
in gastric cancer. OncoImmunology, 4(4). 10.1080/2162402X.2014.1001230. Retrieved from https://hdl.handle.net/10161/11568.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Qi-Jing Li
Adjunct Associate Professor in the Department of Immunology
Recent clinical success in cancer immunotherapy, including immune checkpoint blockades
and chimeric antigen receptor T cells, have settled a long-debated question in the
field: whether tumors can be recognized and eliminated by our own immune system, specifically,
the T lymphocyte. Meanwhile, current limitations of these advanced treatments pinpoint
fundamental knowledge deficits in basic T cell biology, especially in the context
of tumor-carrying patients. Aiming to develop new immunotherapi

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info